(Washington, DC) — A new report from the government’s internal investigative arm details the Food and Drug Administration’s failure to provide adequate drug safety oversight, underscoring the need for more resources and a fundamental reorganization of the agency to protect Americans from dangerous prescription drugs.
Consumers Union, the independent, nonprofit publisher of Consumer Reports, urges Congress to hold hearings on this important,long-awaited GAO report. In addition to hearings, we ask Congress this year to enact bipartisan safety legislation to help prevent
The measures include:
S. 470, HR 3196 — would provide more public information about the clinical trials used to obtain approval of drugs, assuring that data is not hidden or distorted;
S. 930, HR 2090, HR 4429 — would strengthen post-approval safety oversight within the FDA and ensure that FDA can effectively insist on further safety research and the safer advertisement and use of drugs.
To send an email to Congress urging them to strengthen our drug safety laws, click here.